Invivyd (IVVD)
NASDAQ:IVVD
Want to see IVVD full AI Analyst Report?
IVVD Stock Chart & Stats
$1.74
-$0.05(-9.00%)
At close: 4:00 PM EST
$1.74
-$0.05(-9.00%)
Day’s Range― - ―
52-Week Range$0.48 - $3.07
Previous CloseN/A
Volume606.77K
Average Volume (3M)3.49M
Market Cap
$449.66M
Enterprise Value-$11.83M
Total Cash (Recent Filing)$226.69M
Total Debt (Recent Filing)$2.49M
Price to Earnings (P/E)―
Beta1.52
Next Earnings
May 07, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding282,803,860
10 Day Avg. Volume4,837,578
30 Day Avg. Volume3,491,815
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)1.76
Price to Sales (P/S)7.96
P/FCF Ratio-7.30
Enterprise Value/Market Cap-0.03
Enterprise Value/Revenue-0.22
Enterprise Value/Gross Profit-0.24
Enterprise Value/Ebitda0.22
Forecast
1Y Price Target
$10.00Price Target Upside474.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.28
Revenue Forecast (FY)$84.62M
Bulls Say, Bears Say
Bulls Say
Commercial Execution And Financial RunwayStrong launch metrics for PEMGARDA combined with a robust cash position support commercial infrastructure, manufacturing readiness, and the ability to fund pivotal trials without immediate reliance on external financing.
Intramuscular COVID Antibody And Regulatory StrategyProgress toward an intramuscular COVID antibody that can be administered in a standard office or pharmacy setting, paired with regulatory alignment and a trial resizing to strengthen statistical power, improves odds for a clear regulatory readout and easier real-world adoption.
Measles Therapeutic ExpansionDiscovery of a broadly neutralizing monoclonal antibody candidate for measles positions the company to address an unmet need where no symptomatic treatment is authorized, creating a new commercial and public health opportunity and diversifying the pipeline.
Bears Say
Dependence On Pivotal Trial ResultsReliance on pivotal late-stage trial outcomes for the COVID candidate creates a concentrated execution risk where an unfavorable result could substantially impair growth prospects and regulatory plans.
Financing And Shareholder Dilution RiskAnalyst valuation assumptions that incorporate anticipated equity raises imply a meaningful risk of dilution to existing shareholders if clinical or commercial milestones fall short, reducing per-share returns.
Viral Evolution And Efficacy RiskOngoing evolution of the virus could produce strains that escape laboratory neutralization, which would likely translate into reduced protection in people and weaken the antibody's market value.
Invivyd News
IVVD FAQ
What was Invivyd’s price range in the past 12 months?
Invivyd lowest stock price was $0.48 and its highest was $3.07 in the past 12 months.
What is Invivyd’s market cap?
Invivyd’s market cap is $449.66M.
When is Invivyd’s upcoming earnings report date?
Invivyd’s upcoming earnings report date is May 07, 2026 which is in 14 days.
How were Invivyd’s earnings last quarter?
Invivyd released its earnings results on Mar 05, 2026. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of -$0.083 by $0.103.
Is Invivyd overvalued?
According to Wall Street analysts Invivyd’s price is currently Undervalued.
Does Invivyd pay dividends?
Invivyd does not currently pay dividends.
What is Invivyd’s EPS estimate?
Invivyd’s EPS estimate is -0.06.
How many shares outstanding does Invivyd have?
Invivyd has 282,803,860 shares outstanding.
What happened to Invivyd’s price movement after its last earnings report?
Invivyd reported an EPS of $0.02 in its last earnings report, beating expectations of -$0.083. Following the earnings report the stock price went up 1.754%.
Which hedge fund is a major shareholder of Invivyd?
Currently, no hedge funds are holding shares in IVVD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Invivyd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.00 (474.71% Upside)
$10.00 (474.71% Upside)
Blogger Sentiment
Neutral
IVVD Sentiment 50%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 24.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 5.9%
Last 30 Days ▲ 5.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
241.17%
12-Months-Change
Fundamentals
Return on Equity
-48.65%
Trailing 12-Months
Asset Growth
113.78%
Trailing 12-Months
Company Description
Invivyd
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
IVVD Company Deck
IVVD Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed multiple operational and clinical positives: solid PEMGARDA commercial growth (31% QoQ, 25% YoY), durable reorder behavior (77%), a strong year-end cash balance ($226.7M after >$200M raised), Declaration enrollment reaching target, favorable IDMC safety recommendations, and an expanding pipeline (RSV, measles, long COVID). Offsetting items were uncertainties tied to external COVID attack rates that could trigger a ~30% trial upsizing and timing risk to the mid‑2026 readout, limited power to detect rare safety events in small studies (e.g., myocarditis in LIBERTY), and early-stage competition/validation needs for RSV and measles programs. On balance, the positive commercial traction, capitalization, enrollment milestone, and favorable early safety signals outweigh the operational and timing risks.View all IVVD earnings summariesIVVD Stock 12 Month Forecast
Average Price Target
$10.00
▲(474.71% Upside)
Technical Analysis
Larimar Therapeutics
―
Rocket Pharmaceuticals
―
―
4D Molecular Therapeutics
―
Design Therapeutics
―
Ownership Overview
9.90% Insiders
6.30% Mutual Funds
0.02% Other Institutional Investors
77.28% Public Companies and Individual Investors